康宁杰瑞(09966.HK)逆涨11% 两新药临床试验初步结果获美学会肯定
康宁杰瑞制药-B(09966.HK)公布旗下两新药KN026及KN046临床试验初步结果已获即将召开2020年美国临床肿瘤学会(ASCO)年会接受以海报形式呈列。该股今天逆市突破近期小双顶位,最高见19.42元,暂受制2月所创上市高位20.65元,现造18.94元,急弹11%,成交额3,184万元。
康宁杰瑞为一家内地领先临床阶段未获盈利生物科技公司。股份去年12月中旬才以每股10.2元来港上市。公司通告指,目前KN026正分别在中国及美国进行数项II期及I期临床试验,该新药已在晚期乳腺癌患者中表现出良好初步疗效。至於KN046目前正在进行对NSCLC、三阴乳腺癌(TNBC)、食管鳞状细胞癌(ESCC)及胰腺癌的多项II期临床试验。该等临床试验结果将於各种场合发布,该药品有望成为第二代免疫肿瘤治疗药物的基石药物之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.